A combination study of ME-401with Rituxan® in indolent lymphoma & diffuse large B-cell lymphoma (DLBCL)
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2018
At a glance
- Drugs ME 401 (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Lymphoma
- Focus Therapeutic Use
- 30 Aug 2018 According to MEI Pharma media release, company Expecting to initiate this trial by year-end.
- 15 Nov 2017 New trial record
- 08 Nov 2017 MEI Pharma Expecting to initiate this trial in the fourth quarter of 2017, as reported in a media release.